Welcome : Guest

United Therapeutics Corporation (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about United Therapeutics Corporation, which is principally involved in Biotechnology Business. Illustrated with 71 tables, the report showcases the company's recent news stories and events, sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-04023
Price: $3500
Company Type: Public
Pages: 77
Date: November 2016
Market Data Tables: 71

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: United Therapeutics Corporation’s Sales by Product Category Worldwide (2015) in Percentage for Remodulin, Tyvaso, Adcirca, Orenitram, Unituxin, and Others......3
Table 2: United Therapeutics Corporation’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, and Rest of World......4
Biotechnology......8
Table 3: Biotechnology Market by Category in China (2015) - Percentage Share Breakdown by Value for Biopharmaceutical and Chemical......8
Table 4: Biotechnology Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Biopharmaceutical and Chemical......9
Biotesting (Outsourced)......10
Table 5: Outsourced Biotesting Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Environment, Pharma and Others......10
Biotechnology Drugs......11
Table 6: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......11
Pulmonary Arterial Hypertension (PAH)......12
Table 7: Pulmonary Arterial Hypertension (PAH) Treatment by Drug Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Adcirca, Letairis/Volibris, Remodulin, Revatio, Tracleer, Tyvaso and Ventavis......12
Table 8: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy Worldwide (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......13
Table 9: Pulmonary Arterial Hypertension (PAH) Treatment with Macitentan Drug by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Japan, US and Rest of World......14
Table 10: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......15
Table 11: Pulmonary Arterial Hypertension (PAH) Treatment by Type Worldwide (2015) - Percentage Breakdown by Value for Inhaled Prostacyclins, Orals (ERAs, PDE5s, Prostacyclins), and Parenteral Prostacyclins......16
Table 12: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in Europe (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......17
Table 13: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in Europe (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......18
Table 14: Pulmonary Arterial Hypertension Treatment Market by Product Segment in Japan (2015) - Percentage Share Breakdown by Value for Adcirca, Dorner, Flolan, Procylin, Revatio, and Tracleer......19
Table 15: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in the US (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......20
Table 16: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in the US (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......21
Cancer Drugs......22
Table 17: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......22
Table 18: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......23
Cancer Market......24
Table 19: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......24
Table 20: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......25
Table 21: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......26
Table 22: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......27
Table 23: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......28
Table 24: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......29
Table 25: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......30
Table 26: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......31
Cancer Patients......32
Table 27: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......32
Table 28: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......33
Table 29: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......34
Table 30: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......35
Table 31: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......36
Table 32: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......37
Table 33: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......38
Table 34: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......39
Table 35: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......40
Table 36: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......41
Table 37: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......42
Table 38: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......43
Table 39: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......44
Table 40: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......45
Table 41: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......46
Table 42: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......47
Table 43: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......48
Table 44: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......49
Table 45: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......50
Table 46: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......51
Table 47: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......52
Cervical Cancer......53
Table 48: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......53
Table 49: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......54
Hematological Cancer......55
Table 50: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......55
Skin Cancer......56
Table 51: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......56
Cancer-Associated Mucositis......57
Table 52: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......57
Chronic Myelogenous Leukemia (CML)......58
Table 53: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......58
Multiple Myeloma......59
Table 54: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......59
Table 55: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......60
Biotechnology......61
Table 56: Market Shares of Leading Biotechnology Companies Worldwide (2015) - Percentage Breakdown by Value for Amgen, Inc., Merck KGaA, Monsanto Company, Roche Holding AG, Syngenta AG, and Others......61
Table 57: Market Shares of Leading Agricultural Biotechnology Companies Worldwide (2015) - Percentage Breakdown by Research and Development (R&D) Expenditure for Bayer CropScience AG, Dow AgroSciences LLC, DuPont Pioneer, Monsanto Co., Inc., Syngenta AG and Others......62
Table 58: Market Shares of Leading Biotechnology Companies in China (2015) - Percentage Share Breakdown by Value for F. Hoffmann-La Roche Ltd., MERCK SERONO CO., LTD., Novo Nordisk A/S, Qilu Pharmaceutical Co., Ltd. and Others......63
Outsourced Biotesting......64
Table 59: Market Shares of Leading Outsourced Biotesting Companies Worldwide (2015) - Percentage Share Breakdown by Value for Eurofins Scientific, SGS S.A. and Others......64
Colony-Stimulating Factor (GCSF)......65
Table 60: Market Shares of Leading Granulocyte Colony-Stimulating Factor (GCSF) Companies in China (2014) - Percentage Share Breakdown by Value for Amoytop Biotech Co., Ltd., Harbin Pharmaceutical Group Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Qilu pharmaceutical Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd., and Others......65
Cancer Drugs......66
Table 61: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......66
Table 62: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......67
Table 63: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......68
Table 64: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......69
Table 65: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......70
Breast Cancer Drugs......71
Table 66: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......71
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......72
Table 67: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......72
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......73
Table 68: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Other......73
Table 69: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Other......74
Table 70: United Therapeutics Corporation’s Sales by Geographic Region Worldwide (2013) in Percentage for United States and Rest-of-World......75
Table 71: United Therapeutics Corporation’s Sales by Product Category Worldwide (2013) in Percentage for Cardiopulmonary Products (Remodulin, Tyvaso and Adcirca) and Others......76